Penumbra (PEN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Penumbra (PEN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.45 Bn | 11.84 Bn | 253.41 Mn | 56.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.19% |
| Dec 31, 2025 | 130.20% |
| Sep 30, 2025 | 180.96% |
| Jun 30, 2025 | 142.60% |
| Mar 31, 2025 | 692.08% |
| Dec 31, 2024 | 49.89% |
| Sep 30, 2024 | 29.47% |
| Jun 30, 2024 | -109.92% |
| Mar 31, 2024 | -10.82% |
| Dec 31, 2023 | 104.47% |
| Sep 30, 2023 | 48.60% |
| Jun 30, 2023 | 54.43% |
| Mar 31, 2023 | 71.21% |
| Dec 31, 2022 | -26.03% |
| Sep 30, 2022 | -30.05% |
| Jun 30, 2022 | -30.61% |
| Mar 31, 2022 | -80.42% |
| Dec 31, 2021 | -80.87% |
| Sep 30, 2021 | 38.13% |
| Jun 30, 2021 | -14.72% |